More Pricing Power Won't Be 'NICE' to Biopharma: ABPI
By Nuala Moran
Wednesday, March 27, 2013
The shape of the UK's new drug pricing regime became clearer when the government confirmed it is handing responsibility for assessing the value of medicines to the National Centre for Health and Clinical Excellence (NICE), a body that has repeatedly clashed with the industry over its decisions on whether drugs should be funded by the National Health Service.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.